Outcome of the Board Meeting held on 14th November is attached herewith.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lime Chemicals' Board approved unaudited standalone results for Q2 FY26 (quarter ended Sept 30, 2025). Revenue from operations collapsed to Rs 145.51 lakhs in Q2 FY26 from Rs 542.34 lakhs in Q2 FY25 — a drop of roughly 73%. H1 FY26 revenue stood at Rs 330.71 lakhs vs Rs 542.34 lakhs in H1 FY25. The company swung to a loss before tax of Rs 15.94 lakhs in Q2 (vs a profit of Rs 9.91 lakhs a year ago) and posted an H1 loss of Rs 12.55 lakhs. EPS for the quarter was negative at Rs (0.25). The auditor (R.A. Kuvadia & Co.) gave an unmodified review opinion but drew attention to an MSME payment dispute where interest of about Rs 35.35 lakhs has not been provided for. The balance sheet shows other equity in the negative at Rs (470.13) lakhs and current borrowings of Rs 498.57 lakhs against total equity of just Rs 180.34 lakhs.
Sharp revenue collapse and return to losses are negative signals for shareholders. The deeply negative reserves and high short-term borrowings relative to thin equity raise concerns about the company's financial health, though operating cash flow remained marginally positive at Rs 16.94 lakhs in H1. Stock could see pressure given the weak quarterly print.